CAMKK2 and prostate cancer: However, the Pb-Cre;Ptenf/f GEMM, as a relatively benign prostate cancer model, does not allow CAMKK2 to be studied in the context of metastasis or progression to highly aggressive subtypes such as neuroendocrine prostate cancer (NEPC).